药易购“95后”董事豪掷1.2亿元 从实控人手中拿下公司超5%股份 内部人士：是为引进人才

Core Viewpoint - The newly appointed director of YaoYigou, Gan Meng, invested 120 million yuan to acquire 5.23% of the company's shares just three months after joining, raising questions about the company's strategic direction amid its financial struggles [2][5][10]. Shareholder Changes - Prior to the transaction, Li Yanfei held 36.97% of the shares, which decreased to 31.75% after the transfer. Gan Meng's acquisition increased his stake to 5.23% from none [3][5]. - The share transfer involved Gan Meng purchasing 5 million shares at 24 yuan each from Li Yanfei, the actual controller who stepped down as chairman in July [5][11]. Financial Performance - YaoYigou reported a net loss of 742,067.51 yuan for the third quarter, a significant decline compared to the previous year, with total losses reaching 8.36 million yuan in the first three quarters [11][12]. - The company's operating revenue showed a slight increase of 0.21% year-on-year, but the net profit turned negative, indicating a concerning trend in financial health [11][12]. - The cash flow from operating activities has also turned negative, with a net cash flow of -114.15 million yuan for the year-to-date period, reflecting a 397.91% decline compared to the previous year [12][14]. Strategic Implications - Internal sources suggest that Gan Meng's entry as a shareholder is aimed at bringing in talent and supporting the company's diversified development, indicating a strategic shift towards enhancing professional expertise within the organization [10]. - The company is positioning itself in the technology-driven health sector, which necessitates the introduction of more specialized talent to foster collaboration and innovation [10].